Franklin Fuda1, Weina Chen2. 1. Department of Pathology, University of Texas Southwestern Medical Center, BioCenter EB3.234, 2330 Inwood Road, Dallas, TX, 75390-9317, USA. 2. Department of Pathology, University of Texas Southwestern Medical Center, BioCenter EB3.234, 2330 Inwood Road, Dallas, TX, 75390-9317, USA. weina.chen@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: Minimal or measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) is an independent prognostic indicator in acute leukemia. However, the predictive value of MFC MRD is affected by technical challenges, interpretive complexities, and inadequate standardization, particularly in acute myeloid leukemia (AML). Here, we critically review the methodological principles of the MFC MRD assay and discuss clinical implications of MRD. RECENT FINDINGS: Key components of MFC MRD assays to be discussed include the principles of MFC, panel selection, analysis approaches, level of quantifiable MRD and calculation, reporting, and areas of improvements. Key components of clinical implications include context-dependent detection threshold and the integral role of MRD assessment by MFC in the era of ever-expanding molecular testing. With advancements in technology and standardization, MFC along with molecular assays will continue to play an important role in MRD assessment to evaluate treatment response and risk stratification.
PURPOSE OF REVIEW: Minimal or measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) is an independent prognostic indicator in acute leukemia. However, the predictive value of MFC MRD is affected by technical challenges, interpretive complexities, and inadequate standardization, particularly in acute myeloid leukemia (AML). Here, we critically review the methodological principles of the MFC MRD assay and discuss clinical implications of MRD. RECENT FINDINGS: Key components of MFC MRD assays to be discussed include the principles of MFC, panel selection, analysis approaches, level of quantifiable MRD and calculation, reporting, and areas of improvements. Key components of clinical implications include context-dependent detection threshold and the integral role of MRD assessment by MFC in the era of ever-expanding molecular testing. With advancements in technology and standardization, MFC along with molecular assays will continue to play an important role in MRD assessment to evaluate treatment response and risk stratification.
Authors: Dolores Subirá; Susana Castañón; Esther Aceituno; Jaime Hernández; Carmen Jiménez-Garófano; Antonio Jiménez; Ana María Jiménez; Alejandro Román; Alberto Orfao Journal: Am J Clin Pathol Date: 2002-06 Impact factor: 2.493
Authors: Brent Wood; Dragan Jevremovic; Marie C Béné; Ming Yan; Patrick Jacobs; Virginia Litwin Journal: Cytometry B Clin Cytom Date: 2013 Sep-Oct Impact factor: 3.058
Authors: W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis Journal: Leukemia Date: 2015-09-16 Impact factor: 11.528
Authors: Michael J Borowitz; Brent L Wood; Meenakshi Devidas; Mignon L Loh; Elizabeth A Raetz; Wanda L Salzer; James B Nachman; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Cheryl L Willman; Yunfeng Dai; Naomi J Winick; Stephen P Hunger; William L Carroll; Eric Larsen Journal: Blood Date: 2015-06-29 Impact factor: 22.113